Table 3.
Multivariate analysis of prognostic factors correlated with PFS and OS in patients with ENKTCL
| PSF |
OS |
|||
|---|---|---|---|---|
| Variables | HR (95% CI) | p | HR (95% CI) | p |
| Location (nasal/others) | 1.65 (0.92–2.98) | 0.094 | - | - |
| PINK (2–3/0-1) | 0.19 (0.05–0.73) | 0.016 | - | - |
| Elevated LDH (yes/no) | - | - | 1.14 (0.62–2.13) | 0.671 |
| Distal LN involvement (yes/no) |
2.34 (0.77–7.08) | 0.134 | 0.71 (0.32–1.57) | 0.392 |
| Ann Arbor stage III–IV/I–II |
3.70 (1.57–8.73) | 0.003 | 2.01 (0.91–4.44) | 0.083 |
| NRI score (≥2/0-1) | 1.28 (0.68–2.42) | 0.443 | 1.78 (0.85–3.74) | 0.127 |
| Chemotherapy (non-ANT/ANT based) |
0.33 (0.18–0.59) | 0.001 | 0.27 (0.14–0.52) | 0.001 |
| PD-L1 expression (high/low) |
1.46 (0.82–2.62) | 0.200 | 1.75 (0.93–3.28) | 0.081 |
| VISTA expression (high/Low) |
1.48 (0.82–2.68) | 0.198 | 1.32 (0.68–2.55) | 0.412 |
Abbreviation: LDH, lactate dehydrogenase; LN, lymph node; NRI, nomogram-revised risk index; PINK, prognostic index of natural killer lymphoma; ANT, anthracycline; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. p-value <0.05 marked in bold font shows statistically significant.